| First Author | Kwak DE | Year | 2020 |
| Journal | PLoS One | Volume | 15 |
| Issue | 1 | Pages | e0227618 |
| PubMed ID | 31923257 | Mgi Jnum | J:283582 |
| Mgi Id | MGI:6386630 | Doi | 10.1371/journal.pone.0227618 |
| Citation | Kwak DE, et al. (2020) Alterations of aqueous humor Abeta levels in Abeta-infused and transgenic mouse models of Alzheimer disease. PLoS One 15(1):e0227618 |
| abstractText | Alzheimer's disease (AD) is an ageing-related neurodegenerative disease characterized and diagnosed by deposition of insoluble amyloid-beta (Abeta) plaques in the brain. The plaque accumulation in the brain directly affects reduced levels of Abeta in cerebrospinal fluid (CSF) and blood, as Abeta can freely transport the blood-brain barrier, and clinical investigations have suggested these two biofluids as promising samples for in vitro diagnosis. Given that the human eye structurally resembles the brain and Abeta accumulation often observed in the ocular region of AD patients, in this study, we examined aqueous humor Abeta as another possible surrogate biomarker. First, using the acute Abeta-infused AD mouse model by injecting Abeta to the CSF in intracerebroventricular region of normal ICR mice, we investigated whether Abeta concentration in the aqueous humor in AD models is positively correlated with the concentration in the CSF. Then, we examined the correlation of aqueous humor Abeta levels with increased plaque deposition in the brain and reduced Abeta levels in both CSF and blood in adult and aged 5XFAD Alzheimer transgenic mice. Collectively, the synthetic Abeta injected into CSF immediately migrate to the aqueous humor, however, the age-dependently reducing pattern of Abeta levels in CSF and blood was not observed in the aqueous humor. |
